Definition, Prevalence, and Risk Factors of Low Sex Hormone-Binding Globulin in US Adults.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Wang Y;Wang Y
  • Source:
    The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2021 Sep 27; Vol. 106 (10), pp. e3946-e3956.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN: 1945-7197 (Electronic) Linking ISSN: 0021972X NLM ISO Abbreviation: J Clin Endocrinol Metab Subsets: MEDLINE
    • Publication Information:
      Publication: 2017- : New York : Oxford University Press
      Original Publication: Springfield, Ill. : Charles C. Thomas
    • Subject Terms:
      Endocrine System Diseases/*diagnosis ; Endocrine System Diseases/*epidemiology ; Sex Hormone-Binding Globulin/*metabolism; Adult ; Aged ; Aged, 80 and over ; Cardiovascular Diseases/blood ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/etiology ; Cohort Studies ; Diabetes Mellitus/blood ; Diabetes Mellitus/epidemiology ; Diabetes Mellitus/etiology ; Endocrine System Diseases/blood ; Endocrine System Diseases/complications ; Female ; Humans ; Male ; Metabolic Syndrome/blood ; Metabolic Syndrome/epidemiology ; Metabolic Syndrome/etiology ; Middle Aged ; Nutrition Surveys ; Prevalence ; Risk Factors ; Sex Hormone-Binding Globulin/analysis ; Testosterone/blood ; United States/epidemiology ; Young Adult
    • Abstract:
      Context: Lower sex hormone-binding globulin (SHBG) is associated with many diseases including cardiovascular disease, cancer, polycystic ovarian syndrome, arthritis, and liver disease. However, the definition of low SHBG and its prevalence in US adults are unknown.
      Objective: To define low SHBG and to determine its prevalence and risk factors in US adults.
      Design, Setting, and Participants: This cohort study included adults ≥20 years from the US National Health and Nutrition Examination Survey (NHANES) from 2013 to 2016 who had fasting serum SHBG.
      Exposures: NHANES coverage during 2013-2016.
      Main Outcomes Measures: Definition, prevalence, and risk factors of low SHBG.
      Results: This study included 4093 adults (weighted sample size of 204 789 616) with a mean (SD) age of 47.5 (17.0) years. In a "healthy" reference sub-cohort of 1477 adults, low SHBG was defined as SHBG < 12.3 nmol/L in men < 50 years, <23.5 nmol/L in men ≥ 50 years, <14.5 nmol/L in women < 30 years, and <21.9 nmol/L in women ≥ 30 years. The estimated US national prevalence of low SHBG was 3.3% in men, 2.7% in women, and 3.0% overall. Risk factors for this condition in both men and women included higher body mass index, diabetes, ethnicity (being other than Hispanic, non-Hispanic black, or non-Hispanic white), chronic obstructive pulmonary disease, coronary heart disease, and smoking.
      Conclusions: This study established the criteria for low SHBG among US adults. The estimated US national prevalence of low SHBG was 3.3% in men and 2.7% in women.
      (© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.)
    • References:
      Clin Chem Lab Med. 2018 Jun 27;56(7):1152-1160. (PMID: 29729137)
      Stroke. 2020 Apr;51(4):1257-1264. (PMID: 32078494)
      J Clin Endocrinol Metab. 1977 Dec;45(6):1211-9. (PMID: 338622)
      Hypertension. 2003 Dec;42(6):1206-52. (PMID: 14656957)
      J Clin Endocrinol Metab. 2000 Feb;85(2):645-51. (PMID: 10690870)
      J Thromb Haemost. 2012 Oct;10(10):2061-7. (PMID: 22882730)
      J Clin Endocrinol Metab. 2014 Jan;99(1):184-93. (PMID: 24203061)
      Trends Endocrinol Metab. 2015 Jul;26(7):376-83. (PMID: 26044465)
      J Clin Endocrinol Metab. 2020 Mar 1;105(3):. (PMID: 31793624)
      BMC Cardiovasc Disord. 2013 Apr 18;13:30. (PMID: 23594436)
      Int J Urol. 2006 Apr;13(4):354-61. (PMID: 16734850)
      Diabetes Obes Metab. 2004 May;6(3):208-15. (PMID: 15056129)
      J Steroid Biochem. 1987;27(1-3):95-8. (PMID: 3695499)
      Trends Endocrinol Metab. 2012 Jan;23(1):32-40. (PMID: 22047952)
      Int J Endocrinol. 2017;2017:6956495. (PMID: 29213285)
      Ann Clin Biochem. 2020 Jan;57(1):88-94. (PMID: 31679389)
      Horm Cancer. 2015 Feb;6(1):54-63. (PMID: 25523946)
      Clin Chim Acta. 2019 Dec;499:142-148. (PMID: 31525346)
      Vital Health Stat 2. 2020 Apr;(184):1-35. (PMID: 33663649)
      J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):481-5. (PMID: 10419028)
      Horm Metab Res. 2015 Jun;47(7):485-90. (PMID: 25565095)
      J Clin Endocrinol Metab. 2011 Apr;96(4):1053-9. (PMID: 21239514)
      Vital Health Stat 2. 2018 Jan;(177):1-26. (PMID: 29775431)
      Mol Cell Endocrinol. 2010 Mar 5;316(1):79-85. (PMID: 19698759)
      Arthritis Res Ther. 2020 May 18;22(1):118. (PMID: 32423484)
      J Diabetes Investig. 2011 Oct 7;2(5):373-6. (PMID: 24843516)
      J Androl. 1992 Mar-Apr;13(2):107-16. (PMID: 1597394)
      Hum Mol Genet. 2010 Feb 1;19(3):535-44. (PMID: 19933169)
      Am J Cardiol. 2002 Aug 15;90(4):364-8. (PMID: 12161223)
      Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28. (PMID: 30559228)
      Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):1058-1066. (PMID: 32127398)
      J Clin Endocrinol Metab. 2007 Feb;92(2):405-13. (PMID: 17090633)
    • Contributed Indexing:
      Keywords: prevalence; risk factor; sex hormone-binding globulin
    • Accession Number:
      0 (Sex Hormone-Binding Globulin)
      3XMK78S47O (Testosterone)
    • Publication Date:
      Date Created: 20210614 Date Completed: 20211207 Latest Revision: 20211214
    • Publication Date:
      20240829
    • Accession Number:
      PMC8571812
    • Accession Number:
      10.1210/clinem/dgab416
    • Accession Number:
      34125885